Nusinersen not checked

Biogen · BIIB058 · ISIS 396443

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
2 active
15 in total · 4 in the EU
Targets
 

What this is

How it works
A short strand of genetic material that blocks one gene's message, so the body makes less of one protein.Survival Motor Neuron-2-directed RNA Interaction; Antisense Oligonucleotide FDA class
Tested for
Spinal Muscular Atrophy, Muscular Atrophy, Spinal
Main trialPhase 3
“In this study, researchers will learn more about the use of a higher dose of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on teenagers and adults who are unable to walk on their own and who have previously taken another drug for SMA called risdiplam. The main goal of this study is to learn about the effect of high dose (HD) nusinersen on muscle and movement ability (motor function) in SMA. The main question that researchers want to answer is: \- How do the scores of a movement test called the Revised Upper Limb Module change from the start…”In the company’s words, NCT05067790 on ClinicalTrials.gov
Other names
BIIB058 · ISIS SMNRx · ISIS 396443 · Spinraza · IONIS-SMN Rx · Sprinraza

Other drugs for Spinal Muscular Atrophy

All 14 drugs for Spinal Muscular Atrophy

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials15

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 24 Sep 2027 A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
Phase 1Recruiting 30 Sep 2027 A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Phase 4Completed 9 Oct 2025 A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)
Phase 3Terminated 21 Nov 2016 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
Phase 3Completed 20 Feb 2017 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
Phase 3Completed 21 Aug 2023 A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
Phase 3Completed 21 Feb 2024 Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Phase 3Completed 30 Jul 2026 A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
Phase 2Completed 21 Aug 2017 A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)
Phase 2Terminated 24 Sep 2018 A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).
Phase 2Completed 17 Dec 2024 A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Phase 1/2Completed 31 Jan 2015 An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
Phase 1Completed 31 Jan 2013 An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
Phase 1Completed 28 Feb 2014 An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)
Phase 1Completed 31 Jan 2017 An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Nusinersen

Following is part of Solo: you see every change to Nusinersen the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in